Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets

Romeo GR., Lee J., Shoelson SE.

Narrative Review on Type 2 Diabetes, Chronic Inflammation, published in Arterioscler Thromb Vasc Biol (2012) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Arterioscler Thromb Vasc Biol (2012)
Reported sample size
—
Source database
Europe PMC
PMID
22815343
PMCID
PMC4784686
DOI
10.1161/atvbaha.111.241869
Citations
270

Abstract (original English)

Obesity and its comorbidities, including type 2 diabetes mellitus and cardiovascular disease, are associated with a state of chronic low-grade inflammation that can be detected both systemically and within specific tissues. Areas of active investigation focus on the molecular bases of metabolic inflammation and potential pathogenic roles in insulin resistance, diabetes, and cardiovascular disease. An increased accumulation of macrophages occurring in obese adipose tissue has emerged as a key process in metabolic inflammation. Recent studies have also begun to unravel the heterogeneity of adipose tissue macrophages, and their physical and functional interactions with adipocytes, endothelial cells, and other immune cells within the adipose tissue microenvironment. Translating the information gathered from experimental models of insulin resistance and diabetes into meaningful therapeutic interventions is a tantalizing goal with long-term global health implications. In this context, ongoing clinical studies are testing the effects of targeting inflammation systemically on metabolic and cardiovascular outcomes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LeukocytesMacrophagesAnimalsHumansInsulin ResistanceObesityChronic DiseaseInflammationWeight LossAnti-Inflammatory Agents

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research